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Macrophage migration inhibitory factor (MIF) was originally identiﬁed in the culture medium of activated T lymphocytes as a
solublefactorthatinhibitedtherandommigrationofmacrophages.MIFisnowrecognizedtobeamultipotentcytokineinvolvedin
the regulation of immune and inﬂammatory responses. Moreover, the pivotal nature of its involvement highlights the importance
of MIF to the pathogenesis of various inﬂammatory disorders and suggests that blocking MIF may be a useful therapeutic strategy
for treating these diseases. This paper discusses the function and expressional regulation of MIF in several rheumatic diseases and
related conditions.
1.Introduction
An important advance in our understanding of the patho-
genesis of rheumatic diseases such as rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE), and systemic
vasculitis has been the discovery of the associated abnormal
expressionandorchestrationofseveralcytokinesandinﬂam-
matory mediators. Emerging evidence indicates that many
of these molecules play key roles during cell activation and
contribute to the pathogenesis of disease. For example, the
development of the inﬂammatory pannus, which may be the
result of an overproliferation of synoviocytes and inﬁltration
by inﬂammatory and immune cells, and with subsequent
tissue destruction is the histological hallmark of RA [1, 2].
Numerousmediators,includinginﬂammatorycytokinesand
adhesion molecules, have been implicated in this process [3–
6], and it is well known that the orchestration of complicated
cytokine networks plays a pivotal role during the evolution
of synovitis. Among the cytokines involved is macrophage
migration inhibitory factor (MIF), which appears to be an
important mediator of inﬂammatory responses following
its secretion from T lymphocytes, macrophages, endothelial
cells (ECs), and other inﬂammatory cells. In this paper, we
willfocusonthefunctionandexpressionalregulationofMIF
in several rheumatic diseases and related conditions.
2. MIF: Overview
Originally identiﬁed in the culture medium of activated T
lymphocytes as a soluble factor that inhibited macrophage
migration [7], MIF is a highly conserved 12.5-kDa pro-
tein that exhibits a unique combination of hormone-like,
cytokine-like, and thioredoxin-like properties and is now
recognized to be a multipotential cytokine involved in
the regulation of immune and inﬂammatory responses
[8]. A variety of cell populations have been shown to
express and secrete MIF, including T lymphocytes [9],
macrophages/monocytes [10], endothelial cells (ECs) [11],
eosinophils [12], polymorphonuclear neutrophils (PMNs)
[13], epithelial cells [14], smooth muscle cells [15], synovial
ﬁbroblasts [16], and anterior pituitary cells [17], which sug-
geststhatMIFisinvolvedinawidearrayofphysiologicaland
pathophysiological processes. As will be described later in
detail, the pleiotropic nature of this cytokine is illustrated by
thenumerousmechanismsimplicatedinitseﬀects,including
activation of mitogen-activated protein kinase (MAPK)2 Arthritis
signaling [18], upregulated of proinﬂammatory mediators
[8], counterregulation of endogenous glucocorticoids [19,
20] and inhibition of apoptosis [21], among others.
3. Induction of MIF
The proinﬂammatory molecules TNF-α,I L - 5 ,I F N - γ,t r a n s -
forming growth factor β, and lipopolysaccharide (LPS) have
all been shown to stimulate MIF mRNA expression and
protein secretion [8, 12, 22–24]. It also has been shown
that the complement-activated product C5a promotes MIF
release from PMNs in vitro and during sepsis [25]. Toll-
like receptor 4 (TLR4) stimulation is known to induce the
MIF secretion [10] and, intriguingly, TLR2 and TLR4 are
both highly expressed in the synovial tissue of RA patients
[26]. Moreover, stimulation of dendritic cells (DC) from
RA patients with TLR4 ligands elicited higher levels of MIF
production than stimulation of immature DC [27]. Finally,
Paiva et al. recently showed that macrophages produce MIF
upon recognition of immune complex, and the secreted MIF
acts as an autocrine/paracrine enhancer of TNF production
[28].
4. A MIFReceptor
The signal transduction pathways utilized by MIF during
its activation of cells and cellular processes are incompletely
deﬁned, but one MIF receptor is known to be CD74, the
cell surface form of the class II invariant chain [29]. The
interaction of MIF with CD74 has been conﬁrmed in “pull-
down” experiments, and confocal microscopic examination
showed the two proteins to be colocalized within cells [29].
MIF-induced cellular activation appears to be mediated via
MAPK and a transcription factor, activator protein 1 (AP-1);
thatis,MIFappearstosignalviaclassicalreceptor-dependent
activationofMAPKuponbindingtoCD74[29].Inaddition,
recent studies have identiﬁed recruitment of transmembrane
CD44 as a potential accessory protein required for MIF-
CD74 signal transduction [30, 31]. These data show that
the serine phosphorylation of the CD74 intracytoplasmic
domain by MIF stimulation is dependent upon CD44. Of
interest, more recently, crucial roles of chemokine receptors
inMIF-CD74pathwaywereelucidated.Bernhagenetal.have
shown that the chemokine receptors CXCR2 and CXCR4
are functional receptors for MIF [32]. MIF triggered Gαi-
and integrin-dependent arrest and chemotaxis of monocytes
and T cells, rapid integrin activation, and calcium inﬂux
through CXCR2 or CXCR4. Also, CXCR2 and CD74 formed
a receptor complex, and monocyte arrest elicited by MIF
in inﬂamed or atherosclerotic arteries involved both CXCR2
and CD74 [32]. Recent advances in understanding of MIF
signaling pathway may have an important contribution
for new therapeutic strategies for inﬂammatory/immune
diseases. It has been demonstrated that an orally bioavailable
MIF antagonist, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-
i s o x a z o l ea c e t i ca c i dm e t h y le s t e r( I S O - 1 )[ 33], inhibited the
interaction between MIF and CD74 and reduced functional
and histological indices of glomerulonephritis, CD74(+)
andCXCR4(+)leukocyterecruitment,andproinﬂammatory
cytokine and chemokine expression in the NZB/NZW F1
and the MRL/lpr mouse strains, two distinct models of SLE
[34].
5. The Interaction of MIF and Glucocorticoids
MIF is one of cytokine known to be upregulated by
glucocorticoids (GCs), which suggests MIF plays a key role
in regulating host global responses to infections, as GCs
are released from the hypothalamus-pituitary-adrenal axis
[17, 35]. GCs elicit MIF secretion both in vitro and in
vivo, but the manner in which MIF is regulated by GC
appears to be complex. Although very low concentrations of
dexamethasone (10−14 M) stimulate MIF secretion [19, 36],
this induction is not accompanied by changes in MIF gene
expression, and posttranslational mechanisms have been
proposed [37]. On the other hand, Leech et al. showed that
mRNA expression by RA ﬁbroblast-like synoviocytes (FLS)
was induced by the stimulation of lower concentrations of
dexamethasone (10−10−10−12 M) [16]. Upon release, MIF
exerts an inhibitory eﬀect on GC activity. For example,
recombinant MIF counteracts GC-induced suppression of
cytokine production in macrophages and T lymphocytes
[9, 19]. In vivo, MIF overcomes the protective eﬀect of
GCs in murine models of endotoxic shock [19]. And
in an antigen-induced arthritis model, exogenous MIF
reverses the inhibitory eﬀect of GC on arthritis inﬂam-
mation, but does not aﬀect GC-induced inhibition of
delayed-type hypersensitivity, which suggests there are dif-
ferences in the sensitivity of inﬂammatory processes to MIF
[38].
6.BiologicalActivitiesofMIF
6.1.ChemotacticActivities. AlthoughMIFwasﬁrstidentiﬁed
as an inhibitor of macrophage migration [39], induction
of leukocyte rolling, adhesion, and transmigration by LPS
and other inﬂammatory mediators is diminished in MIF−/−
mice [40]. Similarly, blockade or depletion of MIF reduces
leukocyteaccumulationinmodelsofinfection/endotoxemia,
arthritisandatherogenesis[41–43].Nonetheless,MIFclearly
induces adhesion and migration of monocyte-lineage cells
in postcapillary venules, and that function is mediated by
the chemokine CCL2 (MCP-1), which is induced in ECs
by MIF, itself [44]. In addition, expression and secretion
of MIF by vascular smooth muscle cells (VSMCs) is
increased when the cells are stimulated with oxidized low-
density lipoprotein, and recombinant MIF enhances the
migration of VSMCs [45]. This suggests that MIF acts in an
autocrine and paracrine fashion to modulate the migration
of VSMCs, and may be associated with the development
of advanced lesions during the course of atherogenesis.
MIF also induces chemotaxis in ﬁbroblasts [46]a n dE C s
[47], and the eﬀects of neutralizing MIF in experimental
autoimmune myocarditis indicates that it also stimulates
migration T cells [48]. In addition, lipopolysaccharide-
induced leukocyte-EC interaction was promoted by endoge-
nous MIF, via endogenous GC-independent mechanismsArthritis 3
[49]. More recently, Cheng et al. have shown that endoge-
nous MIF promotes leukocyte recruitment via eﬀects on
endothelialexpressionofseveraladhesionmolecules,includ-
ing E-selectin, intercellular adhesion molecule (ICAM-1),
vascularcelladhesionmolecule(VCAM)-1,andchemokines,
including IL-8 (CXCL8) and CCL2 whereas exogenous MIF
facilitates leukocyte recruitment induced by TNF by pro-
moting endothelial P-selectin expression, which contributed
to leukocyte rolling [50]. Thus MIF appears to have broad
eﬀects on the recruitment of leukocytes, VSMCs, ﬁbrob-
lasts, and leukocyte-EC interactions mediated by several
inﬂammatory molecules in inﬂammatory/noninﬂammatory
disorders.
6.2. Induction of Inﬂammatory Cytokines by MIF. MIF stim-
ulates release of the proinﬂammatory cytokines TNF-α,I L -
1, IL-6, IL-8, and IL-12 from macrophages and up-regulates
matrix metalloproteinase (MMP) -1, MMP-3, MMP-9 and
MMP-13 in RA FLS [16, 51–57]. In addition, MIF up-
regulates the adhesion molecules VCAM-1 and ICAM-1 on
ECs and monocytes [58, 59].
In vivo, MIF deﬁciency or neutralization has protective
eﬀectsagainstlethalbacterialsepsisandsepticshockinduced
by Gram-negative endotoxin [17]o rG r a m - p o s i t i v ee x o t o x i n
[60]. In chronic inﬂammatory diseases, MIF reduction is
associated with lower levels of circulating or local TNF
and IL-1 production [61, 62], suggesting MIF is a crucial
regulatorofinﬂammatorycytokineexpression.Invitro,MIF-
deﬁcient cells exhibit impaired TNF production in response
to LPS, an eﬀect mediated via MIF regulation of TLR4-
dependent cellular responses. In diﬀerent experimental
models of sepsis, blocking MIF activity, either through
MIF gene disruption or with anti-MIF antibodies, reduces
cytokine production by downregulating TLR4 expression
[63]. MIF up-regulates macrophage TLR4 expression via the
t r a n s c r i p t i o nf a c t o rP U . 1[ 63].
In contrast to other proinﬂammatory cytokines, MIF
does not induce nuclear translocation of nuclear factor-
(NF-)κB p50 or p60 proteins at concentrations that activate
ERK, and inhibitors of the NF-κB pathway do not inhibit
MIF-induced biological eﬀects on FLS [64]. In addition, a
recent study using an experimental diabetes model showed
that MIF−/−mice are less susceptible to disease induction,
and the reduced susceptibility was associated with lower lev-
els of lymphocyte proliferation and adhesion and decreased
splenic production of IL-23 [65]. Because IL-23 can enhance
IL-17 production [66, 67], it may be that MIF regulates IL-17
indirectly via its eﬀects on IL-23, which is likely involved in
RA and other inﬂammatory disorders.
6.3. Other Activities of MIF. It was recently conﬁrmed that
MIF potently stimulates nitric oxide production, which can
directlymediatecellinjury[68,69]andenhancemacrophage
activities such as intracellular killing, phagocytosis, and
H2O2 production [70]. MIF also acts as a potent angiogenic
factor in autoimmune diseases [71], exerting its angiogenic
eﬀects through induction of such angiogenic mediators as
vascular endothelial growth factor (VEGF) [72, 73].
7. MIF ExpressionandFunction
under Immune/Inﬂammatory Conditions
7.1. MIF in RA. MIF has been implicated in a number
of inﬂammatory and immune-mediated diseases, including
RA [16] and other inﬂammatory arthritis. MIF levels are
increased in synovial ﬂuid and synovial tissue from RA
patients and patients with juvenile idiopathic arthritis [74–
76]. Of interest, synovial MIF immunostaining correlated
strongly with disease activity, and reductions in clinical dis-
ease parameters were accompanied by signiﬁcant reductions
in synovial MIF [74]. Also, Kim et al. have shown that
s e r u mi n ﬂ a m m a t o r ym a r k e r ss u c ha sE S Ra n dC R Pw e r e
correlated with SF levels of MIF, and the SF levels of MIF
were found to be higher in patients with bony erosion than
in those without. In addition, MIF levels correlated with
VEGF levels in both sera and synovial ﬂuids of patients
with RA [72]. MIF activates RA FLSs to produce IL-8,
cyclooxygenase2(COX-2),MMP-1,andMMP-3viatyrosine
kinase-, protein kinase C-, and AP-1-dependent pathways,
which contribute to inﬂammation and tissue destruction
[52, 57]. Also, in another function of MIF in synovial
inﬂammation, the eﬀects of MIF on FLS activation and
proliferation are dependent on extracellular signal-regulated
kinase (ERK) and mitogen-activated protein (MAP) kinase
[64, 74].
Moreover, in animal models for inﬂammatory arthritis
such as adjuvant-induced arthritis, collagen-induced arthri-
tis, and antigen-induced arthritis (AIA), it was clearly shown
that MIF was involved in the pathogenesis of inﬂammatory
arthritis, and the development and severity of the arthritis
and the inﬁltration of inﬂammatory cells into joint tissues
were signiﬁcantly suppressed by administration of an anti-
MIF polyclonal antibody [20, 38, 57, 77], suggesting that
MIF may be functionally active during the development of
arthritis. Furthermore, exogenous MIF inhibited p53 expres-
sion in RA FLS and also increased p53 protein was detected
in cells and synovial tissue derived from MIF−/− mice with
AIA, suggesting that MIF exerts an antiapoptotic eﬀect in
association with its inhibition of p53 in arthritic joints [78].
Finally, recent ﬁnding also indicates that MIF may be one of
crucial target against anti-TNF therapy in patients with RA
[79]. Taken together, these observations indicate that MIF
may play important roles in the evolution of the synovitis
andjointdestructioninRAviamodulationofinﬂammation,
angiogenesis and chemotaxis of inﬂammatory cells.
Although FLS and synovial macrophages are an impor-
tant cellular source of MIF secretion in synovial tissues of RA
[16],MIFwasalsosecretedbydendriticcells(DC)inpatients
with RA [27]. In monocyte-derived dendritic cells (DC)
from RA patients, TLRs signiﬁcantly enhance production of
proinﬂammatory mediators, including MIF, thereby ampli-
fying the proinﬂammatory loop seen in arthritis. Moreover,
stimulation of DC with TLR4 ligands elicited higher levels
of MIF production than stimulation of immature DC from
healthy controls or RA patients [27]. Also TLR4 stimulation
is known to induce the MIF secretion [10]. Intriguingly,
TLR2 and TLR4 are both highly expressed in the synovial
tissue of RA patients, and TLR4 ligands are abundant in4 Arthritis
the serum and synovial ﬂuid of RA patients, suggesting TLR
signaling likely occurs in the synovial compartment of these
patients [26].
The MIF gene is located on chromosome 22q11.2 [80].
The identiﬁcation of a single-nucleotide polymorphism at
position -173 (MIF-173C allele) and a CATT5−8 tetranu-
cleotide repeat element in the promoter region of the MIF
gene has sparked research into the role of these variants
in inﬂammatory conditions. It has also been demonstrated
that the presence of speciﬁc alleles of the MIF CATT
tetranucleotide repeat correlates with the severity of RA [81].
In addition, Barton et al. found that the MIF-173C allele
and the MIF CATT repeat are associated with susceptibility
to inﬂammatory arthritis, but they were unable to ﬁnd a
correlation with disease severity [82]. Martinez showed that
the -173C allele in the MIF promoter region is associated
with an increased predisposition toward RA, mainly in early-
onset patients [83]. The fact that a substantial amount of
evidence points toward a role for MIF in the pathogenesis
of RA prompted investigation of the potential association
between the two MIF genetic variants and the susceptibility
to and severity of RA, using a large cohort of well-
documented, prospectively followed up patients with RA.
Radstake et al. showed that the MIF polymorphisms (-173C
and CATT alleles) are associated with the rate of radiologic
joint damage, but not with RA susceptibility [84]. Increased
MIF levels were shown to correlate strongly with radiologic
joint damage, and carriership of the MIF-173C allele or MIF
CATT allele was associated with markedly higher levels of
circulating plasma MIF, suggesting that MIF expression is
genetically determined and can be used as a novel prognostic
tool in RA [84]. Consistent with that idea, circulating MIF
levels were increased in individuals with juvenile idiopathic
arthritis carrying the MIF-173C functional variant, and
increased susceptibility to the disease was associated with
carriership of either the MIF-173C or CATT allele [75,
76]. It was therefore suggested that for juvenile idiopathic
arthritis, the MIF-173C allele is a predictor of poor outcome
[75].
7.2.MIFinSLE. SLEisanautoimmunediseasecharacterized
by multiorgan damage with inﬁltration of inﬂammatory
cells/immune cells, and the production of autoantibodies.
Although the pathogenesis of SLE has not been fully
elucidated,recentprogresshasprovidedevidencethatseveral
cytokines/chemokines are detectable in the sera and also
damaged organ of SLE patients during active disease.
Besides RA, expression and function of MIF were clearly
demonstrated in SLE and related conditions. Foote et al.
have shown that serum MIF concentrations were positively
associated with SLE disease damage. Also, serum MIF was
positively associated with current corticosteroid dose and
negatively associated with serum creatinine concentration
[85]. A marked increase in both glomerular and tubular MIF
expression was seen in lupus nephritis, and also in focal
segmental glomerulosclerosis (FGS) and mesangiocapillary
proliferative GN [86]. In immunohistochemical study, the
prominent macrophage and T-cell inﬁltrate showed were
largely restricted to areas with marked upregulation of
Stimuli
Cytokines
LPS
TLRs
Inﬂammatory/immune cells
Pannus
IL-1, 6, 8, 12
TNF-α, CCL2, VEGF
inﬂammatory mediators
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Ampliﬁcation of the proinﬂammatory loop by MIF
Glucocorticoids
Gut Brain Kidney
Figure 1: The orchestration of complicated cytokine networks by
MIF in inﬂammatory/immune responses. MIF is a multipotent
cytokine involved in the regulation of immune and inﬂammatory
responses via other various mediators, and plays a key role
in regulating a number of inﬂammatory and immune-mediated
diseases seen in pannus, blood vessels, kidney, gut, and brain.
MIF expression, contributing to glomerular hypercellularity,
glomerular focal segmental lesions, crescent formation,
tubulitis, and granulomatous lesions. In addition, the posi-
tive association of functional polymorphisms of MIF (-173C
and CATT alleles), and the prevalence of SLE was shown by
S´ anchez et al. [87].
In the lupus-prone mice, it has been demonstrated
that renal MIF expression was signiﬁcantly higher in
MRL/lpr mice compared with nondiseased control mice.
Also, MRL/lpr mice with MIF−/− exhibited signiﬁcantly pro-
longed survival, and reduced renal and skin manifestations.
In addition, renal macrophage recruitment and glomerular
injuryweresigniﬁcantlyreducedinMRL/lprmiceMIF−/−,in
association with reduction in CCL2 (macrophage chemoat-
tractant protein-1) [88]. In addition, antiapoptotic eﬀect
was seen in the active lesion of inﬂammatory arthritis as
described above. This function of MIF may be crucial in
the development of SLE, because apoptosis and clearance of
apoptotic cells/material are considered key processes in the
etiology of SLE.
Matsumoto et al. reported that urinary excretion of MIF
is increased in patients with focal glomerular sclerosis and
that urinary MIF levels, are higher in patients with active
glomerular lesions [89]. Immunocytochemical and in situ
hybridization studies have shown that MIF is produced
by local resident glomerular cells [22], and that admin-
istration of a neutralizing anti-MIF antibody dramatically
suppresses an immunologically induced disease model of
rapidly progressive crescentic glomerulonephritis (GN) [61].
In addition, both MIF mRNA and protein were detected in
intrinsic renal cells and glomerular ECs and were markedly
up-regulated in more severe forms of GN (e.g., crescentic
GN)[22,86,90].TheurineMIFconcentrationwasincreasedArthritis 5
Table 1: Biological activities of MIF.
Chemotactic activities
Monocytes stimulation/inhibition:
dependent on its concentration
Tl y m p h o c y t e s
ECs
Vascular smooth muscle cells
Fibroblasts
Angiogenic activities
Antiapoptotic activities
Stimulation of cell proliferation
Induction of mediators
Cytokines TNF-α
I L - 1 ,6 ,8 ,1 2
CCL2
Growth factor VEGF
Adhesion molecules
ICAM-1
VCAM-1
E-selectin
P-selectin
Proteinases MMP-1, 3, 9, 13
Nitric oxide
Superoxide
Chemotactic activities of MIF against monocytes/macrophages may be
dependent on its concentration. VEGF; vascular endothelial growth factor,
ICAM-1; intercellular cell adhesion molecule-1, VCAM-1; vascular cell
adhesion molecule-1, MMP; matrix metalloproteinase.
3.4-fold in proliferative nephropathies and especially in cres-
centic GN (4.5-fold), but not nonproliferative nephropathies
[91].There was a signiﬁcant correlation between the urine
MIF concentration and renal MIF expression, but not with
serum MIF, indicating a renal origin for the excreted urine
MIF. The urine MIF concentration also correlated with
the degree of renal dysfunction, histologic damage, and
leukocytic inﬁltration. Mesangial and tubular epithelial cells,
as well as glomerular capillary ECs, are the major sources
of MIF in GN [22, 90] .T h es e c r e t e dM I Ft h e np r o m o t e s
macrophage activation and secretion of macrophage-derived
cytokines, including IL-1 and ﬁbroblast growth factor,
which may induce mesangial cell proliferation [10, 92].
It thus appears that when combined with other factors,
MIF expressed in the inﬂamed kidney contributes to the
development of the renal damage in GN.
7.3. MIF in Systemic Vasculitis. We recently showed that
serum MIF levels are signiﬁcantly increased in some patients
with systemic vasculitis [94]. Notably, signiﬁcantly elevated
levels of serum MIF were seen in patients with microscopic
polyangiitis (MPA), which is a small vessel vasculitis, but
not in patients with medium vessel vasculitis, such as
polyarteritis nodosa, or large vessel vasculitis, such as giant
cell arteritis and Takayasu arteritis. The elevated MIF levels
seen in MPA patients correlated positively with indexes of
disease activity, including Birmingham vasculitis activity
scores, CRP levels and ESR. Furthermore, MIF levels were
signiﬁcantly diminished in MPA patients exhibiting clinical
improvement after treatment. Similarly, serum MIF levels
were elevated in patients with antineutrophil cytoplasmic
antibody- (ANCA-) related vasculitis [95], as well as in
Wegener’s granulomatous and Kawasaki disease [96]. These
ﬁndings indicate that MIF expression is not speciﬁc to RA,
but may also function as an important regulator of systemic
vasculitis. Serum levels of endothelium-related molecules
such as adhesion molecules and EC-derived cytokines are
reportedly increased in patients with vasculitis [102, 103].
Indeed, vasculitis aﬀecting small vessels may be associated
with dysregulated EC function [104]. In patients with MPA,
for example, the origin of the elevated serum MIF appears
to be ECs and/or inﬂammatory cells such as monocytes
and PMNs [10, 25]. Once secreted, MIF likely participates
in regulating EC proliferation [47] .T h e r ei sa l s oap o s i t i v e
correlation between serum MIF levels and MPO-ANCA
titers in MPA patients [94]. Although there are no data on
the capacity of MPO-ANCA to stimulate secretion of any
cytokine, including MIF, we would expect it to be related
to disease activity and MIF levels, because there appears
to be positive relation between MPO-ANCA titers and
vasculitis disease activity [105]. As mentioned earlier, MIF
up-regulates ICAM-1 on ECs [58], as well as the expression
and secretion of other inﬂammatory cytokines, including
TNF-α and IL-8 [16, 57]. This in turn would be expected to
enhance recruitment of leukocytes to sites of inﬂammation,
which involves adhesion molecule-dependent interactions
with ECs.
We also recently observed that serum MIF levels are
signiﬁcantly higher in RA patients with vasculitis (rheuma-
toid vasculitis; RV) than in those without it (manuscript in
preparation). We found that in RV patients, there are signif-
icant positive correlations between MIF levels and vasculitis
disease activity scores and serum levels of immune complex
anda signiﬁcant negative correlation between MIFlevels and
serum complement levels. Notably, MIF levels in RV patients
also correlated signiﬁcantly with levels of thrombomodulin,
expression of which is associated with endothelial damage
and/or vascular inﬂammation. Collectively, these ﬁndings
suggest dysregulated orchestration of the activities of MIF,
adhesion molecules, and cytokines expressed by ECs and/or
leukocytes plays a crucial role in the development of systemic
vasculitis (e.g., MPA and RV).
7.4. MIF in Other Rheumatic Diseases and Related Conditions.
Serum MIF levels and dermal ﬁbroblast-derived MIF syn-
thesis are both up-regulated in scleroderma, suggesting that
MIF participates in the amplifying proinﬂammatory loop
thatleadstosclerodermaltissueremodeling[97].SerumMIF
levels are also signiﬁcantly elevated in patients with primary
Sj¨ ogren’s syndrome, especially in those with increased γ-
globulins [98]. It has been shown that MIF signaling
stimulates B cell proliferation [106], and that neutralization
of MIF signiﬁcantly inhibits antibody production in vivo [9].
Increased production of MIF might therefore contribute to
hypergammaglobulinemia and possibly reﬂect the disease6 Arthritis
Table 2: Involvement of MIF in various pathological conditions
Diseases References
RA, including rheumatoid vasculitis [16, 27, 52, 57, 72, 74, 79]
Crohn’s disease [54, 93]
Juvenile idiopathic arthritis [75, 76]
Systemic lupus erythematosus [85–87]
Crescentic glomerulonephritis [86, 91]
Focal glomerular sclerosis [89]
Microscopic polyangiitis [94, 95]
Wegener’s granulomas [95]
Kawasaki disease [96]
Systemic sclerosis [97]
Sj¨ ogren’s syndrome [98]
Ankylosing spondylitis [99]
Adult-onset Still’s disease [100]
Relapsing polychondritis [101]
activity of Sj¨ ogren’s syndrome. Ankylosing spondylitis (AS)
is a chronic inﬂammatory disease mainly aﬀecting the
spine and sacroiliac joints. MIF levels were signiﬁcantly
higher in the AS patients than in normal individuals,
which correlated with the Bath Ankylosing Spondylitis
Metrology Index a composite clinical index for AS [99].
Furthermore, important pathogenic contributions of MIF
have been suggested by studies in adult-onset Still’s dis-
ease [100], ocular inﬂammation [107], relapsing polychon-
dritis [101], experimental autoimmune encephalomyeli-
tis, a model of multiple sclerosis [71], inﬂammatory
bowel disease, Crohn’s disease, and experimental colitis
[54, 93].
8. Conclusion
The biological activities of MIF and its relevance in various
diseases are summarized in Tables 1 and 2. The central
involvement of this multifunctional cytokine highlights its
importance in the pathogenesis of inﬂammatory diseases
(Figure 1). Moreover, it suggests that blocking MIF may be
a useful therapeutic strategy for treating these diseases.
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